Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2021 10:48 ET | Source: Hagens Berman Sobol Shapiro LLP

HAGENS BERMAN Reminds FibroGen (FGEN) Investors of Securities Fraud Lawsuit and June 11th Deadline, Encourages Investors with Losses to Contact the Firm

SAN FRANCISCO, May 23, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Oct. 18, 2017 – Apr. 6,...
May 18, 2021 11:48 ET | Source: Hagens Berman Sobol Shapiro LLP

HAGENS BERMAN Encourages FibroGen (FGEN) Investors with Losses to Contact the Firm, Securities Fraud Class Action Filed

SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Oct. 18, 2017 – Apr. 6,...
May 13, 2021 10:16 ET | Source: Hagens Berman Sobol Shapiro LLP

FGEN INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities Fraud

SAN FRANCISCO, May 13, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period:Oct. 18, 2017 – Apr. 6,...
May 03, 2021 14:00 ET | Source: Hagens Berman Sobol Shapiro LLP

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts FibroGen (FGEN) Investors to Securities Fraud Lawsuit and Application Deadline, Advises Investors with Losses to Contact Its Attorneys Now

SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Nov. 8, 2019 – Apr. 6,...
April 12, 2021 10:05 ET | Source: Hagens Berman Sobol Shapiro LLP

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug

SAN FRANCISCO, April 12, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. The firm is investigating possible...
April 07, 2021 16:13 ET | Source: Hagens Berman Sobol Shapiro LLP

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. The firm is investigating possible...